Kramer Anneke, Pippias Maria, Noordzij Marlies, Stel Vianda S, Andrusev Anton M, Aparicio-Madre Manuel I, Arribas Monzón Federico E, Åsberg Anders, Barbullushi Myftar, Beltrán Palma, Bonthuis Marjolein, Caskey Fergus J, Castro de la Nuez Pablo, Cernevskis Harijs, De Meester Johan, Finne Patrik, Golan Eliezer, Heaf James G, Hemmelder Marc H, Ioannou Kyriakos, Kantaria Nino, Komissarov Kirill, Korejwo Grzegorz, Kramar Reinhard, Lassalle Mathilde, Lopot František, Macário Fernando, Mackinnon Bruce, Pálsson Runólfur, Pechter Ülle, Piñera Vicente C, Santiuste de Pablos Carmen, Segarra-Medrano Alfons, Seyahi Nurhan, Slon Roblero Maria F, Stojceva-Taneva Olivera, Vazelov Evgueniy, Winzeler Rebecca, Ziginskiene Edita, Massy Ziad, Jager Kitty J
ERA-EDTA Registry, Department of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
State-financed health institution, City Clinical Hospital #52 of Moscow City Health Department, Moscow, Russia.
Clin Kidney J. 2019 Feb 26;12(5):702-720. doi: 10.1093/ckj/sfz011. eCollection 2019 Oct.
This article summarizes the ERA-EDTA Registry's 2016 Annual Report, by describing the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries.
In 2017 and 2018, the ERA-EDTA Registry received data on patients undergoing RRT for ESRD in 2016 from 52 national or regional renal registries. In all, 32 registries provided individual patient data and 20 provided aggregated data. The incidence and prevalence of RRT and the survival probabilities of these patients were determined.
In 2016, the incidence of RRT for ESRD was 121 per million population (pmp), ranging from 29 pmp in Ukraine to 251 pmp in Greece. Almost two-thirds of patients were men, over half were aged ≥65 years and almost a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 84% of patients. On 31 December 2016, the prevalence of RRT was 823 pmp, ranging from 188 pmp in Ukraine to 1906 pmp in Portugal. In 2016, the transplant rate was 32 pmp, varying from 3 pmp in Ukraine to 94 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2007-11, the 5-year unadjusted patient survival probability on all RRT modalities combined was 50.5%. For 2016, the incidence and prevalence of RRT were higher among men (187 and 1381 pmp) than women (101 and 827 pmp), and men had a higher rate of kidney transplantation (59 pmp) compared with women (33 pmp). For patients starting dialysis and for patients receiving a kidney transplant during 2007-11, the adjusted patient survival probabilities appeared to be higher for women than for men.
本文通过描述2016年36个国家终末期肾病（ESRD）的肾脏替代治疗（RRT）的流行病学情况，总结了欧洲肾脏最佳实践组织（ERA-EDTA）注册中心的2016年度报告。
2017年和2018年，ERA-EDTA注册中心从52个国家或地区肾脏注册机构收到了2016年接受ESRD的RRT患者的数据。总共有32个注册机构提供了个体患者数据，20个提供了汇总数据。确定了RRT的发病率和患病率以及这些患者的生存概率。
2016年，ESRD的RRT发病率为每百万人口121例（pmp），范围从乌克兰的29 pmp到希腊的251 pmp。近三分之二的患者为男性，超过一半的患者年龄≥65岁，近四分之一的患者以糖尿病作为主要肾脏诊断。RRT开始时的治疗方式为84%的患者采用血液透析。2016年12月31日，RRT的患病率为823 pmp，范围从乌克兰的188 pmp到葡萄牙的1906 pmp。2016年，移植率为32 pmp，从乌克兰的3 pmp到西班牙加泰罗尼亚地区的94 pmp不等。对于2007 - 2011年开始接受RRT的患者，所有RRT方式联合的5年未调整患者生存概率为50.5%。2016年，RRT的发病率和患病率男性（分别为187和1381 pmp）高于女性（分别为101和827 pmp），男性的肾脏移植率（59 pmp）高于女性（33 pmp）。对于2007 - 2011年开始透析的患者和接受肾脏移植的患者，调整后的患者生存概率女性似乎高于男性。
